NCT07229716尚未招募1 期
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
Guangdong Hengrui Pharmaceutical Co., Ltd1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年11月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- The maximum plasma concentration (Cmax)
研究概览
简要总结
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntarily sign the informed consent form before the start of the related activities of this trial, and be able to understand the procedures and methods of this trial. Also, be willing to strictly follow the clinical trial protocol to complete this trial.
- •Aged 18-45 years.
- •Male weight ≥ 50 kg, female weight ≥ 45 kg, and body mass index (BMI): 19 - 28 kg/m2 (including both endpoints).
- •Sign the informed consent form and, within 28 days after the last administration of the trial drug, have no intention of having children and agree to adopt non-drug methods of effective contraception, and have no plans for sperm donation or egg donation.
排除标准
- •Those who are allergic to the study drugs (HRS-9813 capsules, nintedanib or pirfenidone), or any components of the study drugs, or have an allergic constitution (such as individuals with asthma, allergic rhinitis, or eczema).
- •Those subjects who, in the judgment of the researchers, have any conditions or diseases that may affect the absorption, metabolism, and/or excretion of the study drug.
- •Those who participated in any clinical trial of other drugs or medical devices within the previous 3 months before the screening period or baseline period, or those whose exposure to the drug is still within 5 half-lives during the study period (whichever is longer).
- •During the screening period or baseline period, the sitting systolic blood pressure was less than 90 mmHg or the sitting diastolic blood pressure was less than 60 mmHg.
- •During the screening period, any one of the following being positive: hepatitis B surface antigen (HBsAg), human immunodeficiency virus antibody, Treponema pallidum antibody or hepatitis C virus antibody.
- •Pregnant or lactating women, or those whose blood pregnancy test results in the screening or baseline phase are positive.
- •Those who have a history of blood donation within 8 weeks before the screening period or the baseline period, or have suffered from severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within 4 weeks before the screening period or the baseline period; or those who plan to donate blood during the trial.
- •Those who were vaccinated within the two weeks prior to the screening period or the baseline period, or those who plan to receive the vaccine during the trial process.
- •Those who have special dietary requirements and cannot follow the uniform diet.
- •Those who have difficulty swallowing, have problems with venous blood collection, or whose physical condition does not allow for intensive blood sampling.
- •Those who have had severe infections, severe trauma or undergone heavy manual surgery within 3 months before the screening period or baseline period; Or those who plan to undergo surgery during the trial period.
- •During the screening period or baseline period, for those with abnormal 12-lead electrocardiogram results and clinical significance, the QTcB of men was > 450ms and that of women was > 460 ms.
- •Those who have a history of smoking (smoking more than 5 cigarettes per day on average) within 3 months before the screening period or baseline period, or those who have a smoking history within 4 weeks before the screening period or baseline period, or those who cannot stop using any tobacco products during the trial period.
- •Those who have a history of drug use or drug abuse/dependence before the screening period or baseline period; Or those with positive urine test results during the baseline period.
- •Those who consumed excessive amounts of tea, coffee or caffeinated beverages (an average of more than 8 cups per day, 250 mL per cup) within 6 months prior to the screening period or baseline period.
研究组 & 干预措施
HRS-9813 Capsule or Nintedanib Soft Capsules or Pirfenidone Tablets Group
Experimental
干预措施: HRS-9813 Capsule (Drug)
HRS-9813 Capsule or Nintedanib Soft Capsules or Pirfenidone Tablets Group
Experimental
干预措施: Nintedanib Soft Capsules (Drug)
HRS-9813 Capsule or Nintedanib Soft Capsules or Pirfenidone Tablets Group
Experimental
干预措施: Pirfenidone Tablets (Drug)
结局指标
主要结局
The maximum plasma concentration (Cmax)
时间窗: From Day 1 to Day 24.
Area under the concentration curve from time 0 to extrapolated infinite time (AUC0-inf)
时间窗: From Day 1 to Day 24.
Area under the concentration curve from time 0 to time of last quantifiable concentration (AUC0-tau)
时间窗: From Day 1 to Day 24.
Area under the concentration curve from time 0 to time t (AUC0-t)
时间窗: From Day 1 to Day 24.
次要结局
- Accumulative excretion rate (Ae)(Day 1, Day 19 and Day 20.)
- Fractional excretion (Fe)(Day 1, Day 19 and Day 20.)
- Renal clearance (CLr)(Day 1, Day 19 and Day 20.)
- Adverse events (AEs)(From Day 1 to Day 30.)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
HRS-9813、吡非尼酮和尼达尼布在健康受试者中的药物相互作用研究CTR2025441320
已完成
4 期
A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationIdiopathic Pulmonary FibrosisNCT02606877Boehringer Ingelheim37
已完成
1 期
Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy SubjectsNCT07049107Jiangsu HengRui Medicine Co., Ltd.14
已完成
1 期
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLCNon Small Cell Lung CancerAdvanced CancerMetastatic Lung CancerSquamous Cell Lung CancerLung CancerNon-Squamous Non-Small Cell Neoplasm of LungNCT03177291H. Lee Moffitt Cancer Center and Research Institute48
进行中（未招募）
4 期
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 PneumoniaNovel Coronavirus-induced Lung FibrosisNCT04856111Post Graduate Institute of Medical Education and Research, Chandigarh48